Equities research analysts predict that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will announce earnings per share of ($0.16) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aurinia Pharmaceuticals’ earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.18). Aurinia Pharmaceuticals reported earnings of ($0.18) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 11.1%. The company is expected to report its next earnings results on Thursday, May 9th.

On average, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.87) to ($0.42). For the next year, analysts expect that the company will report earnings of ($0.34) per share, with EPS estimates ranging from ($0.57) to $0.06. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 8,856.35% and a negative return on equity of 48.16%.

AUPH has been the subject of several recent analyst reports. BidaskClub raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, December 5th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a report on Wednesday, January 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $24.00 price target (up from $18.00) on shares of Aurinia Pharmaceuticals in a report on Tuesday, March 19th. Royal Bank of Canada raised their price target on Aurinia Pharmaceuticals from $9.00 to $11.00 and gave the company a “positive” rating in a report on Wednesday, March 20th. Finally, Raymond James raised their price target on Aurinia Pharmaceuticals from $9.00 to $11.00 and gave the company an “outperform” rating in a report on Wednesday, March 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $13.75.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Aurinia Pharmaceuticals by 7.9% in the 4th quarter. FMR LLC now owns 5,049,740 shares of the biotechnology company’s stock valued at $34,439,000 after purchasing an additional 368,781 shares in the last quarter. Polar Capital LLP increased its stake in Aurinia Pharmaceuticals by 17.8% in the 4th quarter. Polar Capital LLP now owns 3,312,723 shares of the biotechnology company’s stock valued at $22,593,000 after purchasing an additional 501,207 shares in the last quarter. Franklin Resources Inc. increased its stake in Aurinia Pharmaceuticals by 6.1% in the 3rd quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after purchasing an additional 105,300 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in Aurinia Pharmaceuticals by 47.3% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 388,811 shares of the biotechnology company’s stock valued at $2,652,000 after purchasing an additional 124,940 shares in the last quarter. Finally, Creative Planning increased its stake in Aurinia Pharmaceuticals by 10.2% in the 4th quarter. Creative Planning now owns 167,657 shares of the biotechnology company’s stock valued at $1,143,000 after purchasing an additional 15,457 shares in the last quarter. 24.30% of the stock is owned by hedge funds and other institutional investors.

AUPH opened at $6.42 on Friday. The company has a market capitalization of $588.55 million, a PE ratio of -8.45 and a beta of 1.38. Aurinia Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $7.85.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: What is the QQQ ETF?

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.